市場調查報告書
商品編碼
1541732
2024-2032 年按測試類型(巴氏檢測、HPV 檢測、子宮頸活體組織切片、陰道鏡檢查等)、年齡層(20 至 35 歲、35 歲以上)和地區分類的子宮頸癌診斷市場報告Cervical Cancer Diagnostics Market Report by Test Type (Pap Testing, HPV Testing, Cervical Biopsies, Colposcopy, and Others), Age Group (20 to 35 Years, Above 35 Years), and Region 2024-2032 |
2023年,全球IMARC Group宮頸癌診斷市場規模達80億美元。
子宮頸癌診斷依賴一系列先進的實驗室檢查、工具和程序來評估異常細胞或人類乳突病毒 (HPV) 株。它們是透過採集透過錐切術、穿刺活體組織切片、子宮頸內膜刮除術和電線環獲得的組織樣本來進行的,以便在陰道鏡檢查期間對子宮頸進行徹底檢查。檢測後,進行血液、胸部X光、全身電腦斷層掃描(CT)掃描、磁振造影(MRI)、正子斷層掃描(PET)掃描以及膀胱和直腸目視檢查等測試來確定疾病階段。
被診斷患有梅毒、披衣菌、淋病和後天免疫缺乏症候群 (HIV/AIDS) 等性傳染感染 (STI) 的人數大幅增加,導致全球 HPV 感染的風險不斷上升。再加上吸菸者數量的增加,增加了罹患子宮頸癌的機會,這是推動市場成長的關鍵因素之一。此外,人們對早期診斷的認知不斷提高,鼓勵採用可提供快速、準確檢測結果的 HPV 家庭檢測試劑盒。有利的報銷政策的存在也支持了市場的成長。除此之外,對個人化治療計劃的日益偏好正在增加對子宮頸癌診斷的需求。此外,一系列其他治療方案的出現,包括手術、放射治療、化療、錐形活體組織切片、免疫治療和子宮頸切除術,也促進了市場的成長。此外,對開發低成本和高效測試產品的日益重視預計將推動市場成長。
The global cervical cancer diagnostics market size reached US$ 8.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.8% during 2024-2032.
Cervical cancer diagnostics rely on a series of advanced laboratory tests, tools and procedures to evaluate abnormal cells or strains of the human papillomavirus (HPV). They are performed by taking a sample of the tissue obtained through conization, punch biopsy, endocervical curettage and the electrical wire loop for a thorough examination of the cervix during colposcopy. After detection, tests like blood, chest X-ray, body computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan and visual examination of bladder and rectum are conducted to determine the disease stage.
A considerable rise in the number of individuals diagnosed with sexually transmitted infections (STIs), such as syphilis, chlamydia, gonorrhea and acquired immune deficiency syndrome (HIV/AIDS), is escalating the risk of HPV infection worldwide. This, along with the growing number of smokers, which increases the chances of developing cervical cancer, represents one of the key factors bolstering the market growth. Furthermore, the rising awareness about early diagnosis is encouraging the adoption of HPV home testing kits that provide quick and accurate test results. The presence of favorable reimbursement policies also supports the market growth. Apart from this, rising preferences for personalized treatment plans are escalating the demand for cervical cancer diagnostics. Additionally, the availability of a range of other treatment options, including surgery, radiation therapy, chemotherapy, cone biopsy, immunotherapy and trachelectomy, is contributing to the market growth. Moreover, the growing emphasis on developing low-cost and efficient testing products is anticipated to fuel the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cervical cancer diagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on test type and age group.
Pap Testing
HPV Testing
Cervical Biopsies
Colposcopy
Others
20 to 35 years
Above 35 years
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company, Cooper Surgical Inc., F. Hoffmann-La Roche AG, Guided Therapeutics Inc., Hologic Inc., Qiagen, Quest Diagnostics Incorporated and Siemens Healthcare GmbH.